AI-Driven Smart Implantable Drug Delivery Device with Rejection Sensing
An intelligent, soft robotic implant that uses AI to sense scar tissue formation and self-adjusts to maintain precise, long-term drug delivery. By actively bypassing fibrotic encapsulation, this system provides a durable, personalized treatment solution for chronic conditions such as diabetes.
Overview
This intelligent, implantable drug delivery platform represents a breakthrough in long-term therapeutic administration. By integrating soft robotics with artificial intelligence, the device actively manages the body’s natural foreign body response. It autonomously detects the buildup of scar tissue and adapts its mechanical behavior to ensure consistent, personalized drug dosing over extended durations, significantly reducing the need for device replacement.
Technical specifications
The device utilizes a conductive, porous membrane that monitors the implant environment in real-time. By measuring electrical impedance, it identifies when pores are obstructed by cells or fibrous tissue. A proprietary machine learning algorithm processes this data to predict the precise actuation regime required to maintain optimal drug release. The platform employs soft robotic mechanotherapy—characterized by controlled inflation and deflation—to prevent or bypass fibrotic encapsulation. Computational models and bench-top testing have demonstrated the system's ability to maintain consistent dosing even under significant simulated fibrosis, outperforming traditional static implants.
Technology readiness level
The technology is at TRL 4. The research team has successfully demonstrated the system through laboratory validation, computational modeling, and a proof-of-concept deployment in a human cadaveric model using a minimally invasive percutaneous approach. It is currently in the development stage as an academic research project with ongoing transatlantic collaboration.
About University of Galway
University of Galway is a comprehensive public research university on Ireland’s Atlantic coast, combining academic breadth with a strongly applied, partnership‑driven culture. Its integration with University Hospital Galway and the Saolta University Health Care Group gives companies access to clinicians, patients and trial infrastructure for timely translation. For industry, an Innovation Office and an Institute for Clinical Trials offer clear entry points for collaboration, IP and contracting, while proximity to Galway’s medtech hub supports rapid prototyping and validation. Research is supported by competitive national and European programmes, including Science Foundation Ireland and EU funding. A dedicated technology transfer office streamlines IP, licensing and startup formation.
delivered to your inbox.